Astec Lifesciences Q4 Review – CRAMS Likely To Witness Strong Growth Ahead: ICICI Direct

BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Astec Lifesciences Ltd.’s Q4 FY22 numbers were above our estimates across all parameters.

Revenues were up 58% YoY to Rs 272 crore, led by better realizations across key molecules along with higher volumes in the contract manufacturing company (led by ramp up in the herbicide plant utilization).

Revenue from exports market (~ 71% of overall revenue) was up 127.3% YoY to Rs 192.6 crore while the same from the domestic market was down 9% YoY to Rs 79.4 crore.

Astec Lifesciences’ gross margin improved 81 basis points YoY to 39.6%, largely on the back of better realizations vis-a-vis input price inflation, which lifted overall operational performance for the quarter.

Moreover, better growth in the topline led operating leverage, which also supported operating profit margin improvement (up 190 bps) for the quarter.

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

.

Leave a Comment